ClinicalTrials.gg
CompletedNCT01075243Updated Apr 29, 2015Results posted

Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Efficacy

A Phase 4 interventional study of Paracetamol 1000 mg and Paracetamol 650 mg in Post-surgical Dental Pain, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-04-29.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 55 studies in Toothache with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Toothache · United States.

Enrollment
8th of 51
401 · median 193
Started
2009
with 9 others
Phase 4
10 of 55
1 open now
Registered
16th of 55
by date
Lead sponsor
5 of 55
GlaxoSmithKline

Among the 55 studies in Toothache with a site in United States, this one is the 8th largest by enrollment of the 51 interventional ones that give a count, is one of 10 that started in 2009, is one of 10 in phase 4, and was the 16th registered.

Toothache

143 studies on the registry are indexed under Toothache; 29 are open to participants now.

Browse Toothache studies →

Open to participants now

7 of the 55 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Toothache with a site in United States, or all of them as a file.
02

Study summary

GlaxoSmithKline will be conducting this trial to compare analgesic efficacy of paracetamol 1000 mg vs 650 mg. The post-surgical dental pain model will be used to evaluate the analgesic efficacy of paracetamol. Each subject will be enrolled in the study for up to six weeks. The duration of the entire study will be approximately 18 weeks. Each subject will have to come to the clinic for three visits (Screening, Treatment and Follow up visits).

03

Conditions studied

  • Post-surgical Dental Pain

Browse trials for

Keywords

  • dental pain
  • paracetamol
  • Post-surgical dental pain
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 18 to 45 years with moderate-to-severe dental pain as assessed by verbal rating scale (VRS) and confirmed by a score of at least 50 mm out of 100 mm using a visual analogue (VAS) following the surgical removal of up to two mandibular third molars. If only one mandibular third molar is removed, it must be a full bony impaction. If two mandibular third molars are removed, both may be partial bony impactions OR there may be a combination of one full bony impaction with the second tooth being erupted, soft tissue impaction, or partial bony impaction. Ipsilateral maxillary third molars may be removed at the surgeon's discretion, regardless of impaction level.

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating females
  • Allergy/intolerance to study materials or nitrous oxide or local anaesthetic used during surgery
  • Current or recurrent liver, kidney or cardiac disease, stomach ulcers, gastrointestinal bleeding, gastroesophageal reflux disease, bronchospasm, rhinitis, urticaria or asthma
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Paracetamol 1000mg

    Paracetamol 1000mg

    Drug: Paracetamol 1000 mg

  • Experimental
    Paracetamol 650 mg

    Paracetamol 650 mg

    Drug: Paracetamol 650 mg

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Sum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours)

    SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -5.8 (least pain relief) to 40.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]

    Time frame: Every two hours from Baseline to 6 hours post dose

Secondary outcomes

  1. Time to Confirmed First Perceptible Relief

    Participants recorded the time to first perceptible relief by starting the first stopwatch at the time of dosing and stopping it when he/she experienced the first perceptible pain relief. The first perceptible pain relief was confirmed if the participant also stopped the second stopwatch indicating meaningful relief.

    Time frame: Baseline to 6 hours post dose

  2. Time to Onset of Meaningful Pain Relief

    Participants recorded the time to meaningful relief by stopping a second stopwatch when they first began to experience meaningful relief.

    Time frame: Baseline to 6 hours post dose

  3. Time to Start Using Rescue Medication

    Median time of use of rescue medication by participants.

    Time frame: Baseline to 6 hours post dose

  4. Percentage of Participants Who Took Rescue Medication at 2 Hours

    Percentage of participants who received rescue medication at different time points post dose.

    Time frame: Baseline to 2 hours post dose

  5. Percentage of Participants Who Took Rescue Medication at 6 Hours

    Percentage of participants who received rescue medication at different time points post dose.

    Time frame: Baseline to 6 hours post dose

  6. SPRID at 2 Hours

    SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -1.8 (least pain relief) to 12.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief

    Time frame: Every two hours from baseline to 2 hours post dose

  7. SPRID at 4 Hours

    SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -3.8 (least pain relief) to 26.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief

    Time frame: Every two hours from baseline to 4 hours post dose

  8. Total Pain Relief Score (TOTPAR) at 2 Hours

    TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

    Time frame: Every two hours from baseline to 2 hours post dose

  9. TOTPAR at 4 Hours

    TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

    Time frame: Every two hours from baseline to 4 hours post dose

  10. TOTPAR at 6 Hours

    TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

    Time frame: Every two hours from baseline to 6 hours post dose

  11. Sum of Pain Intensity Difference (SPID) Scores at 2 Hours

    SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

    Time frame: Every two hours from baseline to 2 hours post dose

  12. SPID Scores at 4 Hours

    SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

    Time frame: Every two hours from baseline to 4 hours post dose

  13. SPID Scores at 6 Hours

    SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

    Time frame: Every two hours from baseline to 6 hours post dose

  14. Participants Global Assessment to Response to Treatment (PGART)

    PGART was measured by a score in a scale from 0-4: 0- Poor; 1- Fair 2- Good; 3- Very Good; 4- Excellent.

    Time frame: Baseline to 6 hours post dose

07

Results

Posted Apr 29, 2015

Participant flow

Participants were recruited at the clinical site.

Participant flow — Overall Study
MilestoneParacetamol Caplet 1000 Milligrams (mg)Paracetamol Caplet 650 mgPlacebo Caplet
Started16315880
Completed15715580
Not completed630
Withdrew: Lost to follow-up520
Withdrew: Withdrawal by subject110

Outcome measures

PrimarySum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours)

SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -5.8 (least pain relief) to 40.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]

Time frame:
Every two hours from Baseline to 6 hours post dose
Reported as:
Mean · Score on a scale
Sum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours)
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
Sum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours)16.08 ± 10.6812.42 ± 9.894.63 ± 8.82
Statistical analysis
  • Paracetamol Caplet 1000mg vs Paracetamol Caplet 650 mg · ANCOVA · p = 0.0009 · Adjusted mean difference: 3.71 · 95% CI 1.53 to 5.89Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • Paracetamol Caplet 1000mg vs Placebo Caplet · ANCOVA · p = <0.0001 · Adjusted mean difference: 11.33 · 95% CI 8.66 to 14.00Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • Paracetamol Caplet 650 mg vs Placebo Caplet · ANCOVA · p = <0.0001 · Adjusted mean difference: 7.63 · 95% CI 4.94 to 10.31Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
SecondaryTime to Confirmed First Perceptible Relief

Participants recorded the time to first perceptible relief by starting the first stopwatch at the time of dosing and stopping it when he/she experienced the first perceptible pain relief. The first perceptible pain relief was confirmed if the participant also stopped the second stopwatch indicating meaningful relief.

Time frame:
Baseline to 6 hours post dose
Reported as:
Mean · minutes
Time to Confirmed First Perceptible Relief
minutesParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
Time to Confirmed First Perceptible Relief54.72 ± 104.91169.67 ± 120.501225.70 ± 162.884
SecondaryTime to Onset of Meaningful Pain Relief

Participants recorded the time to meaningful relief by stopping a second stopwatch when they first began to experience meaningful relief.

Time frame:
Baseline to 6 hours post dose
Reported as:
Mean · minutes
Time to Onset of Meaningful Pain Relief
minutesParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
Time to Onset of Meaningful Pain Relief70.53 ± 101.47488.16 ± 115.955247.14 ± 143.028
SecondaryTime to Start Using Rescue Medication

Median time of use of rescue medication by participants.

Time frame:
Baseline to 6 hours post dose
Reported as:
Median · minutes
Time to Start Using Rescue Medication
minutesParacetamol Caplet 1000 mgParacetamol Caplet 650 mgPlacebo Caplet
Time to Start Using Rescue Medication360.00 (124.00 to 360.00)314.00 (123.00 to 360.00)131.00 (115.00 to 360.00)
SecondaryPercentage of Participants Who Took Rescue Medication at 2 Hours

Percentage of participants who received rescue medication at different time points post dose.

Time frame:
Baseline to 2 hours post dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Took Rescue Medication at 2 Hours
Percentage of participantsParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
Percentage of Participants Who Took Rescue Medication at 2 Hours0.000.001.30
SecondaryPercentage of Participants Who Took Rescue Medication at 6 Hours

Percentage of participants who received rescue medication at different time points post dose.

Time frame:
Baseline to 6 hours post dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Took Rescue Medication at 6 Hours
Percentage of participantsParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
Percentage of Participants Who Took Rescue Medication at 6 Hours44.2051.9070.00
SecondarySPRID at 2 Hours

SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -1.8 (least pain relief) to 12.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief

Time frame:
Every two hours from baseline to 2 hours post dose
Reported as:
Mean · Score on a scale
SPRID at 2 Hours
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
SPRID at 2 Hours6.49 ± 3.115.57 ± 2.941.55 ± 2.45
SecondarySPRID at 4 Hours

SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -3.8 (least pain relief) to 26.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief

Time frame:
Every two hours from baseline to 4 hours post dose
Reported as:
Mean · Score on a scale
SPRID at 4 Hours
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
SPRID at 4 Hours12.09 ± 6.939.45 ± 6.193.00 ± 5.27
SecondaryTotal Pain Relief Score (TOTPAR) at 2 Hours

TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

Time frame:
Every two hours from baseline to 2 hours post dose
Reported as:
Mean · Score on a scale
Total Pain Relief Score (TOTPAR) at 2 Hours
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
Total Pain Relief Score (TOTPAR) at 2 Hours4.31 ± 1.883.80 ± 1.891.36 ± 1.59
SecondaryTOTPAR at 4 Hours

TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

Time frame:
Every two hours from baseline to 4 hours post dose
Reported as:
Mean · Score on a scale
TOTPAR at 4 Hours
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
TOTPAR at 4 Hours8.21 ± 4.106.64 ± 3.972.79 ± 3.46
SecondaryTOTPAR at 6 Hours

TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].

Time frame:
Every two hours from baseline to 6 hours post dose
Reported as:
Mean · Score on a scale
TOTPAR at 6 Hours
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
TOTPAR at 6 Hours11.06 ± 6.418.83 ± 6.304.29 ± 5.80
SecondarySum of Pain Intensity Difference (SPID) Scores at 2 Hours

SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

Time frame:
Every two hours from baseline to 2 hours post dose
Reported as:
Mean · Score on a scale
Sum of Pain Intensity Difference (SPID) Scores at 2 Hours
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
Sum of Pain Intensity Difference (SPID) Scores at 2 Hours2.17 ± 1.371.77 ± 1.200.19 ± 1.03
SecondarySPID Scores at 4 Hours

SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

Time frame:
Every two hours from baseline to 4 hours post dose
Reported as:
Mean · Score on a scale
SPID Scores at 4 Hours
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
SPID Scores at 4 Hours3.88 ± 3.062.81 ± 2.520.20 ± 2.13
SecondarySPID Scores at 6 Hours

SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.

Time frame:
Every two hours from baseline to 6 hours post dose
Reported as:
Mean · Score on a scale
SPID Scores at 6 Hours
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
SPID Scores at 6 Hours5.02 ± 4.633.59 ± 4.010.34 ± 3.51
SecondaryParticipants Global Assessment to Response to Treatment (PGART)

PGART was measured by a score in a scale from 0-4: 0- Poor; 1- Fair 2- Good; 3- Very Good; 4- Excellent.

Time frame:
Baseline to 6 hours post dose
Reported as:
Mean · Score on a scale
Participants Global Assessment to Response to Treatment (PGART)
Score on a scaleParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
Participants Global Assessment to Response to Treatment (PGART)2.20 ± 1.131.80 ± 1.180.80 ± 1.05

Adverse events

Collected over All adverse events encountered or spontaneously reported following administration of any investigational product, or for up to 5 days after the last administration of investigational product were recorded.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paracetamol Caplet 1000mg—0/163 (0%)28/163 (17.2%)
Paracetamol Caplet 650 mg—0/158 (0%)28/158 (17.7%)
Placebo Caplet—0/80 (0%)18/80 (22.5%)
Most frequent other events
Most frequent other events
EventParacetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo Caplet
NauseaGastrointestinal disorders17/16317/1587/80
HeadacheNervous system disorders4/1636/1587/80
VomitingGastrointestinal disorders7/1635/1584/80

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Paracetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo CapletTotal
Mean19.7 ± 2.2620.4 ± 2.8120.6 ± 2.7620.2 ± 2.61
Sex: Female, Male
Sex: Female, Male(Participants)Paracetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo CapletTotal
Female10210456262
Male615424139
Number of participants with pain severity score measured on a rating scale
Number of participants with pain severity score measured on a rating scale(Participants)Paracetamol Caplet 1000mgParacetamol Caplet 650 mgPlacebo CapletTotal
Moderate10910653268
Severe545227133
08

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
09

References and documents

Publications

  • Yue Y, Collaku A, Brown J, Buchanan WL, Reed K, Cooper SA, Otto J. Efficacy and speed of onset of pain relief of fast-dissolving paracetamol on postsurgical dental pain: two randomized, single-dose, double-blind, placebo-controlled clinical studies. Clin Ther. 2013 Sep;35(9):1306-20. doi: 10.1016/j.clinthera.2013.07.422. Epub 2013 Aug 22. PubMed 23972577 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2010
First posted
Feb 25, 2010
Start
Nov 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Apr 29, 2015
Last update
Apr 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01075243
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 25, 2010
Start date
Nov 2009
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Apr 29, 2015
Last update
Apr 29, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion